MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Sunday, January 30, 2011

Receptos Inc., Initiates Clinical Trials For S1P1 Agonist Program, Aimed At Multiple Sclerosis

January 30, 2011


Receptos, Inc., announced that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study. The study is being conducted in healthy male and female volunteers at a single site in the United States under an Investigational New Drug (IND) application recently allowed by the FDA. Receptos is developing RPC1063 as a potential treatment for multiple sclerosis.

"The progression of RPC1063 into Phase 1 development marks the evolution of Receptos into a clinical stage organization. The exceptional performance of the development team at Receptos has been demonstrated by their ability to initiate clinical trials for our lead compound within 14 months of our Series A funding round"

The study will generate data to confirm that the characteristics of RPC1063 meet pre-specified pharmacokinetic (PK), pharmacodynamic (PD), and safety criteria. These include half-life determination to support once-per-day dosing, and measures that will focus on extent and speed of reversibility of lymphopenia. Safety features will also include observation of cardiovascular, hepatic, lung, and ocular events. The goal of the Phase 1 study will be to utilize the PK-PD relationship of RPC1063 to accurately select dose levels for Phase 2 evaluation. 



READ MORE




***************************************************************
If you find our information worthy, 
then please donate by clicking here 
-- all contributions are tax deductible --
****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
REMAIN up-to-date with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
.
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

No comments: